Regulatory
Retrophin, Inc. announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that it will host a conference call on Thursday, August 1, 2019 at 5pm ET to discuss second quarter 2019 financial results and provide a corporate update.
For LENVIMA plus KEYTRUDA Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
Low cost production and superior product purity of the diabetes drug liraglutide with NUMAFERM’s unique technology platform
Recipharm AB will publish its interim report for January - June 2019 on 25th July at 07:45 am CET.
Revenue and EBITDA for full year 2019 expected to be ahead of market expectations
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
MyoKardia, Inc. announced updates related to its hypertrophic cardiomyopathy treatment portfolio, including lead therapeutic candidate, mavacamten.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
Atriva Therapeutics GmbH announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME.
PRESS RELEASES